Perspective Therapeutics (NYSEAMERICAN:CATX) CEO Purchases $38,070.00 in Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) CEO Johan Spoor acquired 47,000 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average cost of $0.81 per share, with a total value of $38,070.00. Following the transaction, the chief executive officer owned 106,383 shares in the company, valued at approximately $86,170.23. This trade represents a 79.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Perspective Therapeutics Stock Performance

NYSEAMERICAN:CATX traded up $0.10 on Friday, hitting $0.94. The company’s stock had a trading volume of 3,183,208 shares, compared to its average volume of 4,328,272. Perspective Therapeutics, Inc. has a one year low of $0.78 and a one year high of $6.16. The stock has a fifty day moving average of $2.11 and a two-hundred day moving average of $3.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 6.61.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Research analysts expect that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

CATX has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and set a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. William Blair began coverage on Perspective Therapeutics in a research note on Friday, September 18th. They issued an “outperform” rating on the stock. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. Royal Bank Of Canada downgraded Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $14.00 to $4.00 in a research report on Monday, October 26th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.10.

More Perspective Therapeutics News

Investors following CATX have been watching these news items:

• Positive Sentiment: CEO Johan Spoor bought 47,000 shares at an average price of $0.81, increasing his holdings by 79%. Insider Markus Puhlmann also bought 41,000 shares across two transactions at average prices of $0.83 and $0.84. These open-market purchases may signal insiders’ confidence in the company. Insider purchase report
• Positive Sentiment: BMO Capital gave CATX a Buy rating, adding a bullish analyst view. BMO Capital rating
• Negative Sentiment: The company’s latest reported quarter missed expectations: its loss of $0.27 per share was wider than the $0.24 consensus estimate, while revenue of $0.02 million fell short of the $0.06 million forecast. This weak operating performance may weigh on sentiment. CATX earnings information

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Commodore Capital LP purchased a new stake in Perspective Therapeutics in the 1st quarter valued at about $26,424,000. Affinity Asset Advisors LLC lifted its position in shares of Perspective Therapeutics by 954.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after buying an additional 2,864,582 shares in the last quarter. Avidity Partners Management LP lifted its position in shares of Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after buying an additional 2,839,266 shares in the last quarter. Spruce Street Capital LP purchased a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $10,955,000. Finally, Marshall Wace LLP purchased a new position in shares of Perspective Therapeutics in the 3rd quarter worth approximately $4,075,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.